Recorded at the 67th American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, Kelly Bolton, MD, PhD, assistant professor of medicine at Washington University School of Medicine, discusses the ASH abstract (No.635) “Ivosidenib in IDH1-mutant clonal cytopenias of undetermined significance (CCUS): updated results of a phase 2 study.”
The decentralized phase 2 trial showed ivosidenib induced durable hematologic responses in IDH1-mutant CCUS patients with persistent cytopenias, reduced mutant clone burden, and was well tolerated without differentiation syndrome.
